Table 1 Clinical demographics and serum biomarkers
From: 5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity
5ARI users | Non-5ARI users | |
|---|---|---|
Number of patients | 54 | 297 |
Age | 67.6 ± 6.21 | 65.6 ± 6.85 |
Prostate volume | 64.9 ± 33.5 | 48.1 ± 21.8 |
Indication for biopsy | ||
No prior biopsies | 30 (55.6%) | 159 (53.5%) |
Active Surveillance | 3 (5.56%) | 61 (20.5%) |
Prior negative biopsy | 21 (38.9%) | 77 (25.9%) |
Abnormal digital rectal examination | 13 (24.1%) | 72 (24.2%) |
PSA | 11.0 ± 8.33 (22.0 ± 16.7 corrected) | 9.41 ± 8.41 |
PSA density | 0.194 ± 0.142 (0.387 ± 0.284 corrected) | 0.214 ± 0.177 |
PHI | 35.2 ± 16.2 | 47.8 ± 27.1 |
PHI density | 0.667 ± 0.460 | 1.18 ± 0.849 |
Free: Total PSA | 0.127 ± 0.074 | 0.165 ± 0.079 |